Summary of Key Points Core Viewpoint - The average stock price of A-shares is 13.44 yuan, with 32 stocks priced below 2 yuan, the lowest being *ST Gao Hong at 0.44 yuan [1] Group 1: Market Performance - As of September 23, the Shanghai Composite Index closed at 3821.83 points, with a notable presence of low-priced stocks in the market [1] - Among the low-priced stocks, 5 out of 32 increased in price, with Yongtai Energy rising by 6.17%, *ST Yuan Cheng by 2.31%, and Zitian Tui by 2.17% [1] - Conversely, 26 stocks declined, with Yabo Co. falling by 6.01%, Beichen Industry by 5.94%, and Yatai Group by 5.39% [1] Group 2: Low-Priced Stocks Overview - The list of low-priced stocks includes 14 ST stocks, accounting for 43.75% of those priced below 2 yuan [1] - The lowest priced stock is *ST Gao Hong at 0.44 yuan, followed by Zitian Tui at 0.47 yuan and *ST Su Wu at 0.90 yuan [1] - The table of low-priced stocks shows various metrics such as daily price changes, turnover rates, and industry classifications, indicating a diverse range of sectors represented [1][2]

Policy Developments - The Central Commission for Discipline Inspection and the National Supervisory Commission are intensifying efforts to rectify issues in the pharmaceutical sector, focusing on eliminating practices such as medical staff accepting "red envelopes" and improper benefits through academic exchanges [1] Drug and Device Approvals - YKYY013 injection from Yuyuan Pharmaceutical has received FDA approval for clinical trials aimed at treating chronic hepatitis B virus infection, which utilizes a dual-stranded siRNA mechanism to silence the virus [2] - *ST Suwu's hydrochloride lincomycin injection has passed the consistency evaluation for generic drugs, receiving approval from the National Medical Products Administration [3] - Tianjin Pharmaceutical's recombinant human urokinase (Puyouke) has been granted approval for a new indication for thrombolytic treatment of acute ischemic stroke, expanding its product line in the neurological field [4] Capital Market - Lepu Medical has entered into a strategic cooperation agreement with Hanhai Information Technology, aiming to enhance its medical aesthetics business through shared resources and a comprehensive sales network [5] Industry Events - The National Medical Insurance Administration has published the first batch of typical cases involving violations by designated medical institutions, highlighting issues such as falsifying medical records and duplicate charges [6] - Starting January 1, 2025, a new management system for medical insurance payment qualifications will be implemented, introducing a point-based system for violations to ensure the safety of medical insurance funds [7] Research and Development - Researchers at Kunming University of Science and Technology have successfully constructed an in vitro model of the stomach, providing a new platform for studying human gastric organ development [8] Public Sentiment Alerts - Zhejiang Pharmaceutical announced that its shareholder, Guotou Gaoke, plans to reduce its stake by up to 1% within three months, which will not affect the company's control [9]

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. announced that its subsidiary has received approval for the consistency evaluation of Lincomycin Hydrochloride Injection, enhancing its market competitiveness and sales potential [1][3]. Drug Basic Information - Drug Name: Lincomycin Hydrochloride Injection - Dosage Form: Injection - Specification: 2ml: 0.6g (calculated as C18H34N2O6S) - Approval Number: National Drug Approval No. H32021365 - Registration Category: Chemical Drug - Holder of Marketing Authorization: Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. Suzhou Pharmaceutical Factory [1]. Market and Financial Impact - The total sales of Lincomycin Hydrochloride Injection in hospitals nationwide for 2024 are approximately 22.1165 million yuan [3]. - The drug is included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2024) as a Class A variety [3]. - As of August 2025, the company has invested approximately 3.1324 million yuan in the research and development of Lincomycin Hydrochloride Injection [3]. Regulatory and Clinical Use - The drug is indicated for severe infections caused by sensitive strains of Streptococcus, Pneumococcus, and Staphylococcus, specifically for patients allergic to penicillin or deemed unsuitable for penicillin use [2]. - Lincomycin Hydrochloride Injection was first approved by the FDA on December 29, 1964, and has since been approved in various countries, including Japan and European nations [2]. Competitive Advantage - The approval of the drug through the consistency evaluation is expected to positively impact its market sales and competitiveness, as healthcare institutions are encouraged to prioritize the procurement of drugs that have passed this evaluation [3].

Summary of Key Points Core Viewpoint - The average stock price in the A-share market is 13.50 yuan, with 30 stocks priced below 2 yuan, the lowest being *ST Gao Hong at 0.46 yuan [1]. Group 1: A-Share Market Overview - As of September 22, the Shanghai Composite Index closed at 3828.58 points, with the average A-share price at 13.50 yuan [1]. - The distribution of high-priced and low-priced stocks is relatively small in the overall A-share market [1]. Group 2: Low-Priced Stocks - There are 30 stocks priced below 2 yuan, with *ST Gao Hong having the lowest price at 0.46 yuan, followed by Zhi Tian Tui and *ST Su Wu at 0.46 yuan and 0.91 yuan respectively [1]. - Among the low-priced stocks, 14 are ST stocks, accounting for 46.67% of the total [1]. Group 3: Low-Priced Stock Rankings - The table lists various low-priced stocks along with their latest closing prices, daily price changes, turnover rates, and industry classifications [1][2]. - Notable low-priced stocks include *ST Gao Hong (0.46 yuan), *ST Su Wu (0.91 yuan), and *ST Jin Ke (1.41 yuan) [1][2].

公告显示，该品适用于由链球菌、肺炎球菌和葡萄球菌等敏感菌株引起的严重感染，但仅适用于对青霉 素过敏的患者或经医生判断不宜使用青霉素的患者。 北京商报讯（记者 王寅浩 实习记者 宋雨盈）9月22日，*ST苏吴发布公告称，公司全资子公司江苏吴中 医药集团有限公司下属分支机构江苏吴中医药集团有限公司苏州制药厂收到了国家药品监督管理局核准 签发的关于"盐酸林可霉素注射液"的《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致 性评价。 ...

证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-112 规格：2ml：0.6g（按 C18H34N2O6S 计） 药品批准文号：国药准字 H32021365 注册分类：化学药品 江苏吴中医药发展股份有限公司 关于盐酸林可霉素注射液通过仿制药一致性评价的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担个别及连带责任。 近日，江苏吴中医药发展股份有限公司（以下简称"公司"）全资子公司江 苏吴中医药集团有限公司下属分支机构江苏吴中医药集团有限公司苏州制药厂 （以下简称"苏州制药厂"）收到了国家药品监督管理局（以下简称"国家药监 局"）核准签发的关于"盐酸林可霉素注射液"（以下简称"该药品"或"本品"） 的《药品补充申请批准通知书》（通知书编号：2025B04321），该药品通过仿制药 质量和疗效一致性评价（以下简称"仿制药一致性评价"）。现将相关情况公告如 下： 一、药品基本情况 药品名称：盐酸林可霉素注射液 剂型：注射剂 二、药品的其他相关情况 上市许可持有人：江苏吴中医药集团有限公司苏州制药厂 药品生产企业：江苏吴中 ...

根据国家相关政策规定，对于通过仿制药一致性评价的药品品种，在医保支付方面予以适当支持，医疗 机构应优先采购并在临床中优先选用。同品种药品通过仿制药一致性评价的生产企业达到3家以上的， 在药品集中采购等方面不再选用未通过仿制药一致性评价的品种。公司盐酸林可霉素注射液通过仿制药 一致性评价，有利于提升该药品的市场竞争力，对该药品的市场销售产生积极影响。 智通财经APP讯，*ST苏吴(600200.SH)发布公告，近日，公司全资子公司江苏吴中医药集团有限公司下 属分支机构江苏吴中医药集团有限公司苏州制药厂(简称"苏州制药厂")收到了国家药品监督管理局核准 签发的关于"盐酸林可霉素注射液"的《药品补充申请批准通知书》(通知书编号：2025B04321)，该药品 通过仿制药质量和疗效一致性评价。 ...

*ST苏吴公告，全资子公司江苏吴中医药集团有限公司苏州制药厂收到国家药监局核准签发的盐酸林可 霉素注射液《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。盐酸林可霉素注 射液2024年全国医院总销售额约为2211.65万元，已投入研发费用约313.24万元。通过一致性评价有利于 提升该药品的市场竞争力，对公司销售产生积极影响。 ...

Group 1 - The stock of *ST Suwu (600200) closed at 0.95 yuan on September 18, 2025, with an increase of 2.15% and a turnover rate of 4.14% [1] - On September 18, 2025, the net outflow of main funds was 246.04 million yuan, accounting for 8.77% of the total transaction amount [1][3] - The company has been under investigation by the China Securities Regulatory Commission (CSRC) since February 26, 2025, for suspected violations of information disclosure [1] Group 2 - The company received an administrative penalty notice on July 13, 2025, for inflating revenue and profits through transactions with related companies, with inflated revenues reported from 2020 to 2023 totaling 49.53 million yuan, 46.85 million yuan, 43.07 million yuan, and 37.67 million yuan, respectively [1] - The inflated profits during the same period were reported as 1.46 million yuan, 2.03 million yuan, 1.99 million yuan, and 2.12 million yuan [1] - The company’s stock has been subject to a delisting risk warning since July 14, 2025, due to the potential for major illegal delisting circumstances [1][3]

Group 1 - The stock of Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (*ST Suwu) closed at 0.95 yuan on September 18, 2025, with a market capitalization of 675 million yuan, reflecting a 2.15% increase from the previous trading day [1] - The stock experienced a trading volume of 28.05 million yuan and a turnover rate of 4.14% on the same day [1] Group 2 - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. issued its eleventh risk warning regarding the potential for major illegal forced delisting due to suspected violations of information disclosure [2] - The company has been under investigation by the China Securities Regulatory Commission (CSRC) since February 26, 2025, for alleged violations [2] - The company’s subsidiaries were found to have inflated revenue, costs, and profits through transactions with related companies, with inflated revenues reported from 2020 to 2023 totaling approximately 494.26 million yuan, 468.51 million yuan, 430.75 million yuan, and 376.66 million yuan, representing 26.46%, 26.39%, 21.26%, and 16.82% of the respective reported revenues [2] - The inflated total profits during the same period amounted to approximately 14.58 million yuan, 20.27 million yuan, 19.92 million yuan, and 21.22 million yuan [2] - The stock has been subject to delisting risk warnings since July 14, 2025, and if formal penalties confirm delisting criteria, the stock will be terminated from listing [2]